IntroductionMethicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) is a major issue in healthcare, since it is often associated with endocarditis or deep site foci. Relevant morbidity and mortality associated with MRSA-BSIs forced the development of new antibiotic strategies; in particular, this review will focus the attention on fifth-generation cephalosporins (ceftaroline/ceftobiprole), that are the only ss-lactams active against MRSA.Areas coveredThe review discusses the available randomized controlled trials and real-world observational studies conducted on safety and effectiveness of ceftaroline/ceftobiprole for the treatment of MRSA-BSIs. Finally, a proposal of MRSA-BSI treatment flowchart, based on fifth-generation cephalosporins, is described.Expert opinionThe use of anti-MRSA cephalosporins is an acceptable choice either in monotherapy or combination therapy for the treatment of MRSA-BSIs due to their relevant effectiveness and safety. Particularly, their use may be advisable in combination therapy in case of severe infections (including endocarditis or persistent bacteriemia) or in monotherapy in subjects at higher risk of drugs-induced toxicity with older regimens. On the contrary, caution should be taken in case of suspected/ascertained central nervous system infections due to inconsistent data regarding penetration of these drugs in cerebrospinal fluid and brain tissues.

Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future / Bavaro, Davide Fiore; Belati, Alessandra; Bussini, Linda; Cento, Valeria; Diella, Lucia; Gatti, Milo; Saracino, Annalisa; Pea, Federico; Viale, Pierluigi; Bartoletti, Michele. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - ELETTRONICO. - 23:1(2024), pp. 9-36. [10.1080/14740338.2023.2299377]

Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future

Bussini, Linda;Gatti, Milo;Pea, Federico;Viale, Pierluigi;Bartoletti, Michele
2024

Abstract

IntroductionMethicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) is a major issue in healthcare, since it is often associated with endocarditis or deep site foci. Relevant morbidity and mortality associated with MRSA-BSIs forced the development of new antibiotic strategies; in particular, this review will focus the attention on fifth-generation cephalosporins (ceftaroline/ceftobiprole), that are the only ss-lactams active against MRSA.Areas coveredThe review discusses the available randomized controlled trials and real-world observational studies conducted on safety and effectiveness of ceftaroline/ceftobiprole for the treatment of MRSA-BSIs. Finally, a proposal of MRSA-BSI treatment flowchart, based on fifth-generation cephalosporins, is described.Expert opinionThe use of anti-MRSA cephalosporins is an acceptable choice either in monotherapy or combination therapy for the treatment of MRSA-BSIs due to their relevant effectiveness and safety. Particularly, their use may be advisable in combination therapy in case of severe infections (including endocarditis or persistent bacteriemia) or in monotherapy in subjects at higher risk of drugs-induced toxicity with older regimens. On the contrary, caution should be taken in case of suspected/ascertained central nervous system infections due to inconsistent data regarding penetration of these drugs in cerebrospinal fluid and brain tissues.
2024
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future / Bavaro, Davide Fiore; Belati, Alessandra; Bussini, Linda; Cento, Valeria; Diella, Lucia; Gatti, Milo; Saracino, Annalisa; Pea, Federico; Viale, Pierluigi; Bartoletti, Michele. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - ELETTRONICO. - 23:1(2024), pp. 9-36. [10.1080/14740338.2023.2299377]
Bavaro, Davide Fiore; Belati, Alessandra; Bussini, Linda; Cento, Valeria; Diella, Lucia; Gatti, Milo; Saracino, Annalisa; Pea, Federico; Viale, Pierluigi; Bartoletti, Michele
File in questo prodotto:
File Dimensione Formato  
10.108014740338.2023.2299377 (2).pdf

embargo fino al 30/12/2024

Tipo: Postprint
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 831.91 kB
Formato Adobe PDF
831.91 kB Adobe PDF   Visualizza/Apri   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/953171
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact